RBSH.US Rebus Holdings Inc.
- Market cap
- USD 3.21K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is RBSH.US undervalued?
Graham numberThe Graham number of Rebus Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rebus Holdings Inc. fundamental analysis
No fundamental analysis for Rebus Holdings Inc. yet.
Rebus Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rebus Holdings Inc.
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Full company profileRebus Holdings Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rebus Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -21.0K | -21.0K | - | -332K | -35.0K | - | - | - | - |
| Operating Income | -6.40M | -7.00M | -6.07M | -3.19M | -5.85M | -5.85M | -609K | -2.48M | -1.02M | -664K | -486K |
| EBITDA | -6.37M | -6.98M | -6.05M | -3.17M | -16.3M | -5.85M | -121K | -232K | -1.02M | -610K | -260K |
| Net Income | -5.30M | -6.99M | -5.89M | -3.56M | -11.1M | -11.1M | -934K | -6.30M | 1.62M | -1.25M | -762K |
| EPS | -331 | -368 | -245 | -148 | -57,513 | -58 | -0.30 | -0.01 | 0.00 | -0.04 | -0.02 |
| Balance Sheet | |||||||||||
| Total Assets | 3.89M | 2.63M | 2.68M | 734K | 69.0K | 69.0K | 23.0K | 404K | 715K | 5.00K | 9.00K |
| Total Liabilities | 2.63M | 2.53M | 4.59M | 4.16M | 8.92M | 8.92M | 8.75M | 12.9M | 5.74M | 5.24M | 5.62M |
| Shareholders' Equity | 1.26M | 97.0K | -1.91M | -3.43M | -8.85M | -8.85M | -8.72M | -12.5M | -5.02M | -5.24M | -5.61M |
| Cash & Short-term Investments | 3.59M | 2.32M | 2.47M | 547K | 10.0K | 10.0K | 4.00K | 404K | 711K | 5.00K | 5.00K |
| Total Debt | 105K | 105K | - | - | 2.48M | 2.48M | 2.83M | 1.88M | 514K | 310K | 310K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.71M | -5.04M | -4.63M | -2.73M | -1.09M | -1.09M | -313K | -374K | -693K | -706K | -536K |
| Capital Expenditure | 8.00K | 4.00K | 4.00K | 4.00K | 3.00K | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -4.72M | -5.05M | -4.64M | -2.74M | -1.10M | -1.10M | -313K | -374K | -693K | -706K | -536K |
| Ratios | |||||||||||
| ROE | -420.8% | -7,210.3% | - | - | - | - | - | - | - | - | - |
| ROA | -136.5% | -266.0% | -219.8% | -484.3% | -16,087.0% | -16,087.0% | -4,060.9% | -1,558.2% | 225.9% | -25,060.0% | -8,466.7% |
| Debt to Equity | 0.08x | 1.08x | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rebus Holdings Inc. dividends
Rebus Holdings Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:75 on Oct 12, 2021.
Who owns Rebus Holdings Inc.
Ownership data of Rebus Holdings Inc. is not available yet.
Rebus Holdings Inc. company profile
- Company name
- Rebus Holdings Inc.
- Ticker
- RBSH.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 2629 Townsgate Road, Westlake Village, CA, United States, 91361
- Phone
- 818 597 7552
- Website
- rebus-corp.com
About Rebus Holdings Inc.
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
Rebus Holdings Inc. management
3- Mr. Raul Silvestre Esq.CEO, CFO, President, Principal Accounting Officer & Director · born 1971
- Dr. John T. Isaacs Ph.D.Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor
- Dr. Samuel R. Denmeade M.D.Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board